Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Launches Lung Cancer Diagnostic

Premium

Rosetta Genomics this week launched miRview Lung, its microRNA-based diagnostic designed to differentiate neuroendocrine tumors from non-small cell lung tumors, and then subtype neuroendocrine tumors into small cell lung cancer and carcinoid, and non-small cell lung tumors into squamous and non-squamous.

The test will be commercialized in the US by the company's recently formed sales team (GSN 5/5/2011). International sales will be handled by Rosetta's various distribution partners.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.